Search

Your search keyword '"Cappellini,Maria Domenica"' showing total 1,572 results

Search Constraints

Start Over You searched for: Author "Cappellini,Maria Domenica" Remove constraint Author: "Cappellini,Maria Domenica"
1,572 results on '"Cappellini,Maria Domenica"'

Search Results

53. Psychometric evaluation of the NTDT-PRO questionnaire for assessing symptoms in patients with non-transfusion-dependent beta-thalassaemia

54. Dysregulation of Iron Metabolism-Linked Genes at Myocardial Tissue and Cell Levels in Dilated Cardiomyopathy

55. Profile of Luspatercept in the Treatment of Anemia in Adults with Non-Transfusion-Dependent β-Thalassemia (NTDT): Design, Development and Potential Place in Therapy

56. Acid sphingomyelinase deficiency (ASMD): addressing knowledge gaps in unmet needs and patient journey in Italy-a Delphi consensus

60. Current challenges in the management of patients with sickle cell disease – A report of the Italian experience

64. Effect of Luspatercept in β-Thalassemia Patients with β0/β0 Genotype: A Subgroup Analysis of the BELIEVE Study

65. Effect of Luspatercept on Red Blood Cell (RBC) Transfusion Burden, Iron Chelation Therapy (ICT), and Iron Overload in Adults with Transfusion-Dependent β-Thalassemia (TDT) from the BELIEVE Trial: A Long-Term Analysis

67. A Closer Look at Changes in Hemoglobin Levels in Patients with Non-Transfusion Dependent β-Thalassemia Treated with Luspatercept: Post Hoc Analysis of the Phase 2 BEYOND Trial

69. Erythroid Response in Patients with Non-Transfusion-Dependent β-Thalassemia Treated with Luspatercept: Long-Term Data from the BEYOND Trial

71. Efficacy and Safety of a Single Dose of Exagamglogene Autotemcel for Transfusion-Dependent β-Thalassemia

74. Antihypertensive treatment changes and related clinical outcomes in older hospitalized patients

77. Prevalence and Determinants of the Use of Lipid-Lowering Agents in a Population of Older Hospitalized Patients: the Findings from the REPOSI (REgistro POliterapie Società Italiana di Medicina Interna) Study

78. Luspatercept for the treatment of anaemia in non-transfusion-dependent β-thalassaemia (BEYOND): a phase 2, randomised, double-blind, multicentre, placebo-controlled trial

81. The role of hypoxia and inflammation in the regulation of iron metabolism and erythropoiesis in COVID‐19: The IRONCOVID study

82. Morbidity and mortality of sickle cell disease patients is unaffected by splenectomy: evidence from three decades of follow-up in a high-income setting

84. Key terms and definitions in acute porphyrias: Results of an international Delphi consensus led by the European porphyria network.

85. Inhibition of FGF23 is a therapeutic strategy to target hematopoietic stem cell niche defects in β-thalassemia.

86. Bone turnover and mineral density in adult thalassemic patients: relationships with growth hormone secretory status and circulating somatomedins

88. Efficacy and safety of givosiran in patients with acute hepatic porphyria: 36-month results of the phase 3 ENVISION randomised clinical trial

91. An open‐label, multicenter, efficacy and safety study of deferasirox in iron‐overloaded patients with non‐transfusion‐dependent thalassemia ( THETIS ): 5‐year results

92. 385: EFFICACY AND SAFETY OF GIVOSIRAN IN PATIENTS WITH ACUTE HEPATIC PORPHYRIA: 36-MONTH RESULTS OF THE PHASE 3 ENVISION RANDOMIZED CLINICAL TRIAL

Catalog

Books, media, physical & digital resources